Targeting SCF E3 Ligases for Cancer Therapies

27Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.
Get full text

Abstract

SKP1-cullin-1-F-box-protein (SCF) E3 ubiquitin ligase complex is responsible for the degradation of proteins in a strictly regulated manner, through which it exerts pivotal roles in regulating various key cellular processes including cell cycle and division, apoptosis, and differentiation. The substrate specificity of the SCF complex largely depends on the distinct F-box proteins, which function in either tumor promotion or suppression or in a context-dependent manner. Among the 69 F-box proteins identified in human genome, FBW7, SKP2, and β-TRCP have been extensively investigated among various types of cancer in respective of their roles in cancer development, progression, and metastasis. Moreover, several specific inhibitors have been developed to target those E3 ligases, and their efficiency in tumors has been determined. In this review, we provide a summary of the roles of SCF E3 ligases in cancer development, as well as the potential application of miRNA or specific inhibitors for cancer therapy.

Author supplied keywords

Cite

CITATION STYLE

APA

Liu, J., Peng, Y., Zhang, J., Long, J., Liu, J., & Wei, W. (2020). Targeting SCF E3 Ligases for Cancer Therapies. In Advances in Experimental Medicine and Biology (Vol. 1217, pp. 123–146). Springer. https://doi.org/10.1007/978-981-15-1025-0_9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free